Vulvar lichen sclerosus: recent advances in understanding and management
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20213887Keywords:
Vulvar lichen sclerosus, Review, Etiopathogenesis, Diagnosis, TreatmentAbstract
Vulvar lichen sclerosus (VLS) is a chronic inflammatory disorder, which affects women of all ages. It is one of the most common pathologies presenting to vulvar clinics. However, uncertainty continues to exist about its etiopathogenesis, diagnosis and treatment. Studies suggest a multifactorial origin as far as etiology is concerned, including a genetic, autoimmune, hormonal and local infectious background. There is often a delay in diagnosis of VLS due to its asymptomatic nature and lack of awareness in patients as well as physicians. Embarrassment of patients due to private nature of the disease and failure to examine the genital skin properly are the other reasons for delay in diagnosis. Conventionally, treatment includes topical corticosteroids as a first-line therapy with alternative options such as topical calcineurin inhibitors, topical and systemic retinoids, other steroid creams, various destructive techniques and surgical removal of affected tissues. New therapeutic approaches are coming into effect in gynecological practice due to potential risks of the above-mentioned methods. Stem cell and platelet-rich plasma therapy, energy-based modalities such as the fractional CO2 laser, photo dynamic therapy, and high intensity focused ultrasound, and new topical medicines, are some of the new options applied to improve the efficacy of treatment avoiding the side effects of conventional methods. Refinement of surgical techniques for restoring vulvar anatomy is leading to improved patient outcomes. This review summarizes current perspectives on the etiopathogenesis, diagnosis and treatment for vulvar lichen sclerosus.
References
Krapf JM, Mitchell L, Holton MA, Goldstein AT. Vulvar Lichen Sclerosus: Current Perspectives. Int J Women's Health 2020;12:11-20.
Bleeker MCG, Visser PJ, Overbeek LIH, Beurden MV, Berkhof J. Lichen sclerosus: incidence and risk of vulvar squamous cell carcinoma. Cancer Epidemiol Biomarkers Prevention 2016;25:1224-30.
Nair PA. Vulvar Lichen Sclerosus et Atrophicus. J Mid-Life Health. 2017;8:55-62.
Schlosser BJ, Mirowski GW. Lichen sclerosus and lichen planus in women and girls. Clin Obstet Gynecol. 2015;58:125-142.
Funaro D. Lichen sclerosus: A review and practical approach. Dermatol Ther. 2004;17:28-37.
Singh N, Ghatage P. Etiology, clinical features, and diagnosis of vulvar lichen sclerosus: a scoping review. Obstet Gynecol Int. 2020;2020:7480754.
Christmann-Schmid C, Hediger M, Gr€oger S, Krebs J, G€unthert AR. Vulvar lichen sclerosus in women is associated with lower urinary tract symptoms. Int Urogynecol J. 2018;29(2):217-21.
Halonen P, Jakobsson M, Heikinheimo O, Gissler M, Pukkala E. Incidence of lichen sclerosus and subsequent causes of death: a nationwide Finnish register study. BJOG. 2020;127:814-9.
Van de Nieuwenhof HP, Van der Avoort I, De Hullu JA. Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol. 2008;68:131-56.
Gao X-H, Barnardo MCMN, Winsey S, Ahmad T, Cook J, Agudelo JD. The association between HLA DR, DQ antigens, and vulval lichen sclerosus in the UK: HLA DRB112 and its associated DRB112/DQB10301/04/09/010 haplotype confers susceptibility to vulval lichen sclerosus, and HLA DRB10301/04 and its associated DRB10301/04/DQB10201/02/03 haplotype protects from vulval lichen sclerosus. J Invest Dermatol 2005;125:895-9.
Tran DA, Tan X, Macri CJ, Goldstein AT, Fu SW. Lichen Sclerosus: an auto-immuno-pathogenic and genomic enigma with emerging genetic and immune targets. Int J Biol Sci. 2019;15:1429-39.
Kazandi M, Sahin C, Terek MC. Borrelia in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. J cutaneous Pathol. 2010;37:571-7.
Terlou A, Santegoets LAM, Van der Meijden WI, Heijmans-Antonissen C, Swagemakers SMA, Van der Spek P. An autoimmune phenotype in vulvar lichen sclerosus and lichen planus: a Th1 response and high levels of MicroRNA-155. J Invest Dermatol 2012;132:658-66.
Ren L, Zhao Y, Huo X, Wu X. MiR-155-5p promotes fibroblast cell proliferation and inhibits FOXO signaling pathway in vulvar lichen sclerosis by targeting FOXO3 and CDKN1B. Gene. 2018;653:43-50.
Godoy CAP, Teodoro WR, Velosa APP, Garippo AL, Eher EM, Parra ER. Unusual remodeling of the hyalinization band in vulval lichen sclerosus by type V collagen and ECM 1 protein. Clinics. 2015;70:356-62.
Zhao Y, Zhao S, Li H, Qin X, Wu X. Expression of galectin-7 in vulvar lichen sclerosus and its effect on dermal fibroblasts. Oncol Lett. 2018;16:2559-64.
Goldstein AT. Biomarkers of lichen sclerosus NCT03561428. Clinicaltrials.gov. June 2019. Available at: https://clinicaltrials.gov/ct2/show/NCT03561428. Accessed on January 3, 2020.
Kazandi M, Sahin C, Terek MC, Cirpan T, Oztekin K. Clinical evaluation of vulvar lichen sclerosus: case series. Euro J Gynaecol Oncol. 2010;31:555-8.
Taylor AH, Guzail M, Al-Azzawi F. Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. Br J Dermatol. 2008;158:319-28.
Kirtschig G. Lichen sclerosus-presentation, diagnosis and management. Dtsch Arztebl Int. 2016;113:337-43.
Hodges KR, Wiener CE, Vyas AS, Turrentine MA. The female genital self-image scale in adult women with vulvar lichen sclerosus. J Low Genit Tract Dis. 2019;23:210-3.
Gujral S, Coelho J, Chummun S, Watts A. Management of Vulval Lichen Sclerosus-The Role of the Plastic Surgeon. Availabe at: www.ePlasty.com. Accessed on April 24, 2019.
Micheletti L, Preti M, Radici G. Vulvar lichen sclerosus and neoplastic transformation. J Lower Genital Tract Disease. 2016;20:180-3.
Naswa S, Marfatia YS. Physician-administered clinical score of vulvar lichen sclerosus: A study of 36 cases. Indian J Sex Transm Dis. 2015;36:174-7.
Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F. British association of dermatologist’s guidelines for the management of lichen sclerosus 2018. Br J Dermatol. 2018;178:823-4.
Lee A, Bradford J, Fischer G. Long-term management of adult vulval lichen sclerosus. A prospective cohort study of 507 women. JAMA Dermatol. 2015;151(10):1061-7.
Borghi A, Corazza M, Minghetti S, Bianchini E, Virgili A. Dermoscopic features of vulvar lichen sclerosus in the setting of a prospective cohort of patients: new observations. Dermatology. 2016;232:71-7.
Yordanov A, Tantchev L, Kostov S, Slavchev S, Strashilov S, Vasileva P. Vulvar leukoplakia: therapeutic options. Menopause Rev. 2020;19:135-9.
Kirtschig G, Becker K, Günthert A, Jasaitiene D, Cooper S, Chi C-C. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. J Eur Acad Dermatol Venereol. 2015;29(10):e1-43.
Singh N, Mishra N, Ghatage P. Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review. Cureus. 2021;13:e13527.
Yordanov AD, Vasileva PP, Strashilov SA, Konsoulova A. Treatment of vulvar leukoplakia with TheresienOL- A new opportunity. Arch Balkan Med Union. 2019;54:753-8.
Eshtiaghi P, Sadownik LA. Fact or fiction? Adipose-derived stem cells and platelet-rich plasma for the treatment of vulvar lichen sclerosus. J Low Genit Tract Dis. 2019;23:65-70.
Rangatchew F, Knudsen J, Thomsen MV, Drzewiecki KT. Surgical treatment of disabling conditions caused by anogenital lichen sclerosus in women: an account of surgical procedures and results, including patient satisfaction, benefits, and improvements in health-related quality of life. J Plast Reconstr Aesthet Surg. 2017;60:501-8.
King M, Rubin R, Goldstein AT. Current uses of surgery in the treatment of genital pain. Current Sexual Health Rep. 2014;6:252-8.
Rouzier R, Haddad B, Deyrolle C, Pelisse M, Moyal-Barracco M, Paniel BJ. Perineoplasty for the treatment of introital stenosis related to vulvar lichen sclerosus. Am J Obstet Gynecol. 2002;186:49-52.
Wyman AM, Lafranchise E, Lynch C. External use of an oxidized regenerated cellulose agent in the treatment of labial agglutination in postmenopausal women. Obstet Gynecol. 2018;132:1238-40.
